奥妥珠单抗联合来那度胺治疗初治高肿瘤负荷滤泡性淋巴瘤的2期研究
这项单中心2期试验纳入90例初治高肿瘤负荷滤泡性淋巴瘤患者,给予奥妥珠单抗联合来那度胺6周期诱导后24周期维持治疗。2年无进展生存率为93.3%,30个月完全缓解率为89.7%,中位随访70.7个月中位无进展生存未达到,安全性可控。
要点
- 初治高肿瘤负荷滤泡性淋巴瘤患者接受奥妥珠单抗联合来那度胺方案,2年无进展生存率为93.3%。
- 30个月完全缓解率为89.7%,中位随访70.7个月中位无进展生存未达到。
- 最常见任何级别不良事件为腹泻61.1%、斑丘疹53.3%、乏力52.2%。
核心结论
- 对于初治高肿瘤负荷滤泡性淋巴瘤患者,奥妥珠单抗联合来那度胺可带来稳健且持久的缓解,2年无进展生存率良好,安全性可控。
研究设计与样本
- 单中心2期试验,纳入90例初治高肿瘤负荷滤泡性淋巴瘤患者,给予6周期诱导联合治疗后续24周期维持治疗。
主要发现
- 2年无进展生存率为93.3%(95%置信区间88.2-98.6),中位随访70.7个月中位无进展生存未达到。
- 30个月完全缓解率为89.7%(95%置信区间81.3-95.2)。
- 任何级别最常见不良事件为腹泻61.1%、斑丘疹53.3%、乏力52.2%。
- ≥3级最常见不良事件为中性粒细胞减少18.9%、斑丘疹11.1%、肺炎6.7%。
关键数值与推荐
- 入组标准包括滤泡性淋巴瘤1-3a级、II-IV期、东部肿瘤协作组体能状态评分≤2、器官功能充足、符合Groupe d'Étude des Lymphomes Folliculaires标准的高肿瘤负荷。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) has a clinical course that is often characterized by high response rates to first-line therapy, followed by multiple relapses over a prolonged natural history. Currently, there are multiple possible approaches to frontline therapy for untreated advanced-stage FL, but there is an ongoing debate around what is the preferred approach. Based on the benefits seen with combining lenalidomide, an immunomodulatory agent, with rituximab, an anti-CD20 antibody, we aimed to evaluate the safety and efficacy of lenalidomide in combination with obinuzutumab, an anti-CD20 antibody with enhanced antibody-dependent cellular cytotoxicity. The eligibility criteria included a diagnosis of FL, grade 1 to 3a, stage II to IV, Eastern Cooperative Oncology Group performance status ≤ 2, adequate organ function, and high tumor burden according to the Groupe d'Étude des Lymphomes Folliculaires criteria. Participants received 6 cycles of induction with the combination, followed by 24 cycles of maintenance. Among 90 patients, the primary end point, 2-year progression-free survival (PFS), was 93.3% (95% confidence interval [CI], 88.2-98.6), and the median PFS was not reached with a median follow-up of 70.7 months. The complete response rate at 30 months was 89.7% (95% CI, 81.3-95.2). The most common adverse events (AEs) of any grade were diarrhea (61.1%), maculopapular rash (53.3%), and fatigue (52.2%). The most common AEs ≥ grade 3 were neutropenia (18.9%), maculopapular rash (11.1%), and pneumonia (6.7%). In this single-center trial, these findings indicate that, for patients with previously untreated, high tumor burden FL, obinutuzumab and lenalidomide led to robust and durable responses with a favorable 2-year PFS and manageable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT02871219.
引用
- Akkad N, Feng L, Westin JR, et al. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Adv. 2025. PMID: 40517417. doi:10.1182/bloodadvances.2025016483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。